山口大学医学部附属病院は山口県宇部市にある国立大学法人山口大学医学部附属の大学病院である。特定機能病院の一つであり、山口県における先進医療を担う病院の一つ。

During the past decade, Yamaguchi University Hospital conducted 56 clinical trials. In the 10-year time frame, 56 clinical trials started and 23 clinical trials were completed, i.e. on average, 41.1% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 20 clinical trials were completed. i.e. 58.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yamaguchi University Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 10 trials, followed by "Hoffmann-La Roche" with 9 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Incyte Corporation" with 4 trials sponsored and "Pfizer" with 4 trials sponsored. Other sponsors include 33 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yamaguchi University Hospital" #1 collaborator was "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Asahi Kasei Medical Co., Ltd." with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Boston Scientific Japan K.K." with 1 trials as a collaborator and "Brigham and Women's Hospital" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Yamaguchi University Hospital" are "Prostatic Neoplasms" (6 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Non-Small Cell Lung Cancer" (4 trials), "Advanced Hepatocellular Carcinoma" (2 trials) and "Alopecia Areata" (2 trials). Many other conditions were trialed in "Yamaguchi University Hospital" in a lesser frequency.

Most popular intervention types in "Yamaguchi University Hospital" are "Drug" (56 trials), "Biological" (11 trials), "Other" (6 trials), "Device" (4 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "Pembrolizumab" (8 trials), "Carboplatin" (5 trials), "Cisplatin" (5 trials) and "Docetaxel" (5 trials). Other intervention names were less common.

The vast majority of trials in "Yamaguchi University Hospital" are 56 trials for "All" genders, 10 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Yamaguchi University Hospital". undefined are not yet recruiting, 19 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Yamaguchi University Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Yamaguchi University Hospital, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 48 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".